The promising results of anaplastic lymphoma kinase (ALK) inhibitors have changed the significance of ALK fusions in several types of cancer. These fusions are no longer mere research targets or diagnostic markers, but they are now directly linked to the therapeutic benefit of patients. However, most available tumor tissues in clinical settings are formalin-fixed and paraffin-embedded (FFPE), and this significantly limits detailed genetic studies in many clinical cases. Although recent technical improvements have allowed the analysis of some known mutations in FFPE tissues, identifying unknown fusion genes by using only FFPE tissues remains difficult. We developed a 5′-rapid amplification of cDNA ends-based system optimized for FFPE tissues and evaluated this system on a lung cancer tissue with ALK rearrangement and without the 2 known ALK fusions EML4-ALK and KIF5B-ALK. With this system, we successfully identified a novel ALK fusion, KLC1-ALK. The result was confirmed by reverse transcription-polymerase chain reaction and fluorescence in situ hybridization. Then, we synthesized the putative full-length cDNA of KLC1-ALK and demonstrated the transforming potential of the fusion kinase with assays using mouse 3T3 cells. To the best of our knowledge, KLC1-ALK is the first novel oncogenic fusion identified using only FFPE tissues. This finding will broaden the potential value of archival FFPE tissues and provide further biological and clinical insights into ALK-positive lung cancer.
References
[1]
Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, et al. (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263: 1281–1284.
[2]
Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, et al. (1994) Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9: 1567–1574.
[3]
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693–1703.
[4]
Kimura H, Nakajima T, Takeuchi K, Soda M, Mano H, et al. (2011) ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. Lung Cancer.
[5]
Kijima T, Takeuchi K, Tetsumoto S, Shimada K, Takahashi R, et al. (2011) Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer. Cancer Sci 102: 1602–1604.
[6]
Nakajima T, Kimura H, Takeuchi K, Soda M, Mano H, et al. (2010) Treatment of Lung Cancer with an ALK Inhibitor After EML4-ALK Fusion Gene Detection Using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. J Thorac Oncol 5: 2041–2043.
[7]
Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, et al. (2010) Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 363: 1727–1733.
[8]
Gambacorti-Passerini C, Messa C, Pogliani EM (2011) Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 364: 775–776.
[9]
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561–566.
[10]
Rikova K, Guo A, Zeng Q, Possemato A, Yu J, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190–1203.
[11]
Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, et al. (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15: 3143–3149.
[12]
Lamant L, Dastugue N, Pulford K, Delsol G, Mariame B (1999) A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 93: 3088–3095.
Colleoni GW, Bridge JA, Garicochea B, Liu J, Filippa DA, et al. (2000) ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am J Pathol 156: 781–789.
[15]
Hernandez L, Pinyol M, Hernandez S, Bea S, Pulford K, et al. (1999) TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 94: 3265–3268.
[16]
Touriol C, Greenland C, Lamant L, Pulford K, Bernard F, et al. (2000) Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 95: 3204–3207.
[17]
Tort F, Pinyol M, Pulford K, Roncador G, Hernandez L, et al. (2001) Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab Invest 81: 419–426.
[18]
Lamant L, Gascoyne RD, Duplantier MM, Armstrong F, Raghab A, et al. (2003) Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer 37: 427–432.
[19]
Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, et al. (2002) Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 34: 354–362.
[20]
Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, et al. (2000) TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 157: 377–384.
[21]
Bridge JA, Kanamori M, Ma Z, Pickering D, Hill DA, et al. (2001) Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 159: 411–415.
[22]
Ma Z, Hill DA, Collins MH, Morris SW, Sumegi J, et al. (2003) Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 37: 98–105.
[23]
Debiec-Rychter M, Marynen P, Hagemeijer A, Pauwels P (2003) ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 38: 187–190.
[24]
Panagopoulos I, Nilsson T, Domanski HA, Isaksson M, Lindblom P, et al. (2006) Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int J Cancer 118: 1181–1186.
[25]
Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, et al. (1997) A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 89: 1483–1490.
[26]
Gascoyne RD, Lamant L, Martin-Subero JI, Lestou VS, Harris NL, et al. (2003) ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 102: 2568–2573.
[27]
Van Roosbroeck K, Cools J, Dierickx D, Thomas J, Vandenberghe P, et al. (2010) ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica 95: 509–513.
[28]
Takeuchi K, Soda M, Togashi Y, Ota Y, Sekiguchi Y, et al. (2010) Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica.
[29]
Debelenko LV, Raimondi SC, Daw N, Shivakumar BR, Huang D, et al. (2011) Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol 24: 430–442.
[30]
Sugawara E, Togashi Y, Kuroda N, Sakata S, Hatano S, et al. (in press) Identification of ALK Fusions in Renal Cancer: Large-Scale Immunohistochemical Screening by intercalated Antibody-Enhanced Polymer Method. Cancer.
[31]
Du XL, Hu H, Lin DC, Xia SH, Shen XM, et al. (2007) Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. J Mol Med 85: 863–875.
[32]
Jazii FR, Najafi Z, Malekzadeh R, Conrads TP, Ziaee AA, et al. (2006) Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol 12: 7104–7112.
[33]
Lin E, Li L, Guan Y, Soriano R, Rivers CS, et al. (2009) Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 7: 1466–1476.
[34]
Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, et al. (2009) EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 174: 661–670.
[35]
Takeuchi K, Soda M, Togashi Y, Sugawara E, Hatano S, et al. (2011) Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification. Clin Cancer Res 17: 3341–3348.
[36]
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, et al. (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244–285.
[37]
Yamamoto M, Takeuchi K, Shimoji M, Maniwa T, Isaka M, et al. (in press) Small non-mucinous bronchioloalveolar carcinoma with ALK immunoreactivity: A novel ALK fusion gene? Cancer Sci.
[38]
Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, et al. (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14: 6618–6624.
[39]
Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, et al. (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68: 4971–4976.
[40]
Onishi M, Kinoshita S, Morikawa Y, Shibuya A, Phillips J, et al. (1996) Applications of retrovirus-mediated expression cloning. Exp Hematol 24: 324–329.
[41]
Stenoien DL, Brady ST (1997) Immunochemical analysis of kinesin light chain function. Mol Biol Cell 8: 675–689.
[42]
Rahman A, Kamal A, Roberts EA, Goldstein LS (1999) Defective kinesin heavy chain behavior in mouse kinesin light chain mutants. J Cell Biol 146: 1277–1288.
[43]
Houtman SH, Rutteman M, De Zeeuw CI, French PJ (2007) Echinoderm microtubule-associated protein like protein 4, a member of the echinoderm microtubule-associated protein family, stabilizes microtubules. Neuroscience 144: 1373–1382.
[44]
Sablin EP (2000) Kinesins and microtubules: their structures and motor mechanisms. Curr Opin Cell Biol 12: 35–41.
